Trial Search Results
Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT
Accurate measurements from a non-invasive test like myocardial perfusion positron emission tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such as cardiac catheterization.The investigators wish to see if the measurements from cardiac catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: GE Healthcare
Stanford Investigator(s):
Intervention(s):
- Diagnostic Test: Cardiac Perfusion Rest/Stress Digital PET/CT
- Drug: N-13 ammonia
- Drug: Regadenoson
Eligibility
Inclusion Criteria:
- Patient is ≥ 18 years old at the time of the scan
- Patient has known or suspected coronary artery disease
- Patient has had a recent or will be scheduled for a diagnostic coronary angiogram
- Patient provides written informed consent
- Patient is referred for myocardial perfusion scan
- Patient is capable of complying with study procedures
- Patient is able to remain still for duration of imaging procedure (approximately 60
minutes total for both PET/CT)
Exclusion Criteria:
- Patients who are pregnant or breast feeding
- Patients with contraindications to regadenoson
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jordan Ciscernos
650-725-6409
Recruiting